Series C Momentum ImmunOs has recently closed an $11 million Series C financing in September 2024, signaling strong investor confidence and a runway for advancing IOS-1002 into broader trials and potential partnerships.

Strategic Partnerships Active and recent collaborations with Merck (2023) and Keytruda (2024) indicate openness to combination therapies, suggesting BD conversations around co-development, access to checkpoint inhibitors, and accelerated paths to clinical proof.

Lead Program Focus IOS-1002 is ImmunOs' lead program advancing to Phase 1 in solid tumors, presenting a near-term entry point for pharma partners interested in HLA-based immune modulators and potential combo strategies with PD-1/PD-L1, CTLA-4, or CD47 axes.

Manufacturing Partnerships Existing large-scale manufacturing partnership with ProBioGen for IOS-1002 demonstrates capability and willingness to scale, opening opportunities for co-manufacturing agreements, technology transfer, and supply chain collaborations.

Clinical & Regulatory Readiness Experienced leadership hires in CMC and Technical Development and a dedicated Scientific Advisory Board indicate a readiness to engage in regulatory discussions, scalable GMP production, and robust data packages for potential pharma license deals or strategic collaborations.